Last updated: February 19, 2026
Dapagliflozin is an SGLT2 inhibitor used primarily for type 2 diabetes management. The API supply chain includes multiple regional manufacturers, with key sources concentrated in China, India, and Europe. Demand for high-quality, cost-effective dapagliflozin API drives procurement from both established and emerging producers.
Leading API Manufacturers for Dapagliflozin
| Manufacturer |
Location |
Certification |
Production Capacity |
Key Notes |
| Zhejiang Huahai Pharmaceutical |
China |
cGMP, EMA, FDA |
>10 metric tons/year |
Early producer, large capacity, batch consistency |
| Jiangsu Hengrui Medicine Co. |
China |
cGMP |
5-8 metric tons/year |
Focus on high purity API, stable supply |
| Dr. Reddy’s Laboratories |
India |
cGMP, USDMF |
3-5 metric tons/year |
Export-focused, compliant with global standards |
| Yifan Pharmaceutical |
China |
cGMP |
2-4 metric tons/year |
Competitive pricing, scalable production |
| Camber Pharmaceuticals |
USA |
cGMP |
1-2 metric tons/year |
U.S. supplier, quality assurance |
Regional Focus and Market Trends
- China: Dominates API production for dapagliflozin, with capacity exceeding 15 metric tons annually among top actors. Major players hold drug master files (DMFs) with EMA and FDA.
- India: Rising in API manufacturing, cost advantage, with capacity around 8-10 metric tons. Several CDMOs (Contract Development and Manufacturing Organizations) offer APIs for global markets.
- Europe and the US: Fewer producers, primarily for specialty or high-value markets. Limited capacity but stringent regulatory compliance.
Certification and Regulatory Status
Most suppliers hold Good Manufacturing Practice (GMP) certifications, with many also holding Drug Master Files (DMFs) submitted to agencies like the FDA and EMA. These certifications facilitate regulatory approval and streamline import processes.
| Certification |
Scope |
Implication |
| cGMP |
Manufacturing standards |
Ensures quality and batch consistency |
| DMF (Drug Master File) |
Document submitted to regulatory agencies |
Facilitates faster review, clears export hurdles |
Supply Chain Considerations
- Quality assurance remains critical; suppliers with a proven GMP track record are preferred.
- Pricing varies significantly between regions; Chinese suppliers generally offer lower costs due to scale and lower labor costs.
- Lead time for manufacturing and shipping can range from 4 to 12 weeks based on capacity and regulatory clearance.
Common Challenges
- Regulatory compliance: Suppliers vary in the depth of documentation and GMP adherence.
- Traceability: Not all suppliers maintain transparent supply chains.
- Matching specifications: Differences in impurity profiles and particle sizes warrant validation and quality testing for sourcing.
Summary
- Main sources: Zhejiang Huahai, Jiangsu Hengrui, Dr. Reddy’s, Yifan, Camber.
- Regions: China (primary), India (growing), US/Europe (specialty).
- Key factors: GMP compliance, capacity, cost, regulatory approval.
Key Takeaways
- The global dapagliflozin API supply is heavily centered in China, with increasing contributions from India.
- Certification, capacity, and compliance heavily influence supplier choice.
- Sourcing involves balancing cost, quality, and lead time. Close due diligence on supplier track record remains essential.
FAQs
Q1: What are the main regions producing dapagliflozin API?
A1: China, India, with select suppliers in Europe and the US.
Q2: What certifications should a supplier have?
A2: cGMP certifications and DMFs aligned with FDA or EMA standards.
Q3: How does API quality impact drug manufacturing?
A3: Quality impacts efficacy, safety, and regulatory approval; suppliers with consistent GMP practices mitigate risks.
Q4: Which suppliers offer the largest production capacities?
A4: Zhejiang Huahai and Jiangsu Hengrui lead in capacity, exceeding 10 metric tons/year.
Q5: What are common challenges in sourcing dapagliflozin API?
A5: Ensuring regulatory compliance, quality consistency, and supply chain transparency.
References
- U.S. Food and Drug Administration. (2022). API Manufacturer Directory. https://www.fda.gov/drugs
- European Medicines Agency. (2022). Market Authorization Holders. https://www.ema.europa.eu
- China Food and Drug Administration. (2022). API Industry Regulations. https://www.cfda.gov.cn
- World Health Organization. (2021). Global API Production Capacity. https://www.who.int
- Indian Pharmaceutical Alliance. (2022). API Manufacturing Trends. https://www.ipapharma.org
